Get the Stockscreener App
26.71
6.12%
1.54
Enliven Therapeutics Inc stock is traded at $26.71, with a volume of 1.24M.
It is up +6.12% in the last 24 hours and up +57.95% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$25.17
Open:
$25.34
24h Volume:
1.24M
Relative Volume:
1.40
Market Cap:
$1.59B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-14.13
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+2.73%
1M Performance:
+57.95%
6M Performance:
+24.46%
1Y Performance:
+21.46%
1-Day Range:
$24.82
$27.46
1-Week Range:
$23.25
$27.46
52-Week Range:
$13.30
$29.98
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
26.71 | 1.49B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Have Enliven Therapeutics Insiders Been Selling Stock? - Sahm
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. attractive for institutional investorsQuarterly Market Summary & High Return Trade Opportunity Guides - bollywoodhelpline.com
Moving Averages: Does Enliven Therapeutics Inc stock have upside surprise potential2025 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN - Investing.com Canada
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 9,635 Shares - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8%Here's What Happened - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares - Investing.com India
Enliven Therapeutics Insider Sold Shares Worth $3,476,014, According to a Recent SEC Filing - marketscreener.com
Stocks with rising relative price strength: Enliven Therapeutics - MSN
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s Why - Defense World
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data - Sahm
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - FinancialContent
Enliven Therapeutics (NASDAQ:ELVN) Trading 21.1% HigherTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com - Investing.com India
Enliven Therapeutics stock hits 52-week high at $25.64 - Investing.com
Enliven reports positive initial phase 1b data for ELVN-001 in CML - Investing.com Nigeria
Enliven Therapeutics, Inc. (ELVN): Investor Outlook Reveals 78% Potential Upside In Biotech Sector - DirectorsTalk Interviews
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Why Enliven Therapeutics Inc. stock could benefit from AI revolution2025 Earnings Surprises & Growth Focused Entry Point Reports - ulpravda.ru
What risks investors should watch in Enliven Therapeutics Inc. stockWeekly Earnings Recap & Technical Analysis for Trade Confirmation - ulpravda.ru
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data - Yahoo Finance
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Analyst Calls & Long-Term Growth Stock Strategies - Улправда
Is Enliven Therapeutics Inc. stock attractive for hedge fundsTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Enliven touts drug trial results, adds pharma exec to board - BizWest
Enliven Therapeutics’ Initial Leukemia Drug Data Excite Investors, Shares Surge - Bitget
Will Enliven Therapeutics Inc. stock see insider buyingWeekly Stock Report & AI Forecasted Stock Moves - Улправда
Enliven Stock Soars 51% After Positive CML Trial Results - Nasdaq
How supply chain issues affect Enliven Therapeutics Inc. stock2025 Retail Activity & Free Risk Controlled Daily Trade Plans - Улправда
Shorts Report: How Enliven Therapeutics Inc. stock reacts to oil pricesFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
Enliven surges on trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? - Stocktwits
How resilient is Enliven Therapeutics Inc. stock in market downturns2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Enliven Stock Soars On Promising Phase 1b Data In Chronic Myeloid Leukaemia - Nasdaq
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month HighHere's Why - MarketBeat
Enliven reports positive initial phase 1b data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PR Newswire
Enliven Appoints Scott Garland to Board, Focuses on ELVN-001 Commercialization - Intellectia AI
Enliven Therapeutics continues to prepare for phase 3 trial initiation in 2026 - marketscreener.com
Scott Garland joins Enliven Therapeutics board as company prepares for CML trial - Investing.com Nigeria
Scott Garland joins Enliven Therapeutics board as company prepares for CML trial By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Jan 09 '26 |
Sale |
27.22 |
91,198 |
2,482,578 |
765,188 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Jan 08 '26 |
Sale |
24.05 |
41,302 |
993,436 |
856,386 |
| Heyman Richard A. | Director |
Jan 08 '26 |
Sale |
25.03 |
9,635 |
241,156 |
25,545 |
| Heyman Richard A. | Director |
Jan 09 '26 |
Sale |
25.00 |
4,285 |
107,125 |
25,107 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):